Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00301522 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,108
- Enrollment target
NCT00301522: Completed Phase 2 study, sponsored by Boston Scientific Corporation.
NCT00301522 is a Phase 2 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,108 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (733% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00301522, a Phase 2 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,108 participants
- Enrollment target
Study Summary
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
Interventions
- DEVICE Express2
- DEVICE TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,108 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00301522 record still lists
NCT00301522 is an interventional study that assigns participants to a tested intervention. Its 1,108 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (733% higher).
The record links to 0 conditions, and to 2 interventions - of which Express2 is the first listed.
NCT00301522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00301522 about?
NCT00301522 is a clinical study titled "Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions". The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
What is the current status of trial NCT00301522?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,108 participants. The study started on 2003-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00301522?
The interventions under investigation include: Express2 (DEVICE), TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation (DEVICE).
Who is sponsoring clinical trial NCT00301522?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00301522's enrollment target sits among peer trials
1,108 21st of 2000 higher than 1,980 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia